NYSE American · Biotechnology · USD
Oragenics, Inc. (OGEN) Stock Analysis
Oragenics, Inc. (OGEN) is a Biotechnology stock listed on NYSE American and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
OGEN Key Statistics
As of Oct 21, 2026Trading
- Open
- $0.44
- Previous Close
- $0.43
- Day's Range
- 0.41–0.43
- 52-Week Range
- 0.41–1.36
- Volume
- 5.33K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.26
Valuation
- Market Cap
- $1.86M
- P/E Ratio
- unprofitable
- PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
- −8.96
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −2.44
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$9.84M
- Shares Outstanding
- 4.51M
- 1-Year Return
- −69.87%
Dividend and dates
- Avg Volume
- 29.60K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, OGEN closed at $0.41, −69.87% over 1 year.
Oragenics, Inc. (OGEN) has a market capitalization of $1.86M.
In fiscal 2025, OGEN reported revenue of $0.00.
OGEN Stock Return by Calendar Year
Oragenics, Inc. (OGEN) 10-year return: what $10,000 became
- 1 year
- $10,000 $3,013
- −69.87%
- 5 years
- $10,000 $4
- −99.96%
- 10 years
- $10,000 $0.52
- −99.99%
If you had invested $10,000 in Oragenics, Inc. (OGEN) 10 years ago, at the close on October 21, 2016, it would have been worth $0.52 at the close on October 21, 2026: −99.99% in total, −62.70% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −47.08% |
| 2025 | −92.97% |
| 2024 | −93.43% |
| 2023 | −14.70% |
| 2022 | −75.56% |
| 2021 | +0.00% |
| 2020 | −13.46% |
| 2019 | −39.53% |
| 2018 | −62.61% |
| 2017 | −57.41% |
| 2016 (partial year) | −28.00% |
As of October 21, 2026.
OGEN Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$9.84M | — |
| 2024 | $0.00 | −$10.57M | — |
| 2023 | $0.00 | −$20.66M | — |
| 2022 | $0.00 | −$14.29M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$9.36M | −$9.84M | — |
| 2024 | $0.00 | — | −$10.56M | −$10.57M | — |
| 2023 | $0.00 | — | −$20.90M | −$20.66M | — |
| 2022 | $0.00 | — | −$14.42M | −$14.29M | — |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
Recent News
Oragenics Chief Medical Officer to Present at IPAC-RS 2026 Nasal Innovation Forum
YahooOragenics Advances Phase IIa Trial With 9 Participants Dosed; Recieved NYSE American Non Compliance Letter, Has 45 Days From Receipt Of The Deficiency Letter Within Which To Submit A Plan To Regain Compliance With The Continued Listing Standards
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B